Sensorion: first cohort recruited for Audiogene

(CercleFinance.com) - Sensorion announces the completion of enrolment in the first cohort of the Audiogene clinical trial as part of the Phase 1/2 gene therapy study, with a third patient injected with the SENS-501 gene therapy product in December 2024.


For all patients treated in the first cohort, the surgical procedure was well tolerated: intra-cochlear administration of the gene therapy product was uneventful, and no serious adverse events were reported", says Sensorion.

Audiogene is the first gene therapy clinical trial involving a unique homogeneous population of infants and young children (aged six to 31 months at the time of injection) who have never received cochlear implants.

The trial was designed not only to evaluate the ability of SENS-501 to restore hearing, but also to enable infants and young children to acquire and develop normal language.

Copyright (c) 2024 CercleFinance.com. All rights reserved.